Patients receiving post-transplant cyclophosphamide to prevent graft-versus-host disease have lower risk for bronchiolitis obliterans syndrome.

SNY secures EU conditional approval for Rezurock to treat chronic GVHD in adults and children aged 12 years and older.

The MarketWatch News Department was not involved in the creation of this content. Results from the Precision-T study showed Orca-T significantly improved survival free from chronic GvHD in patients ...

Hematopoietic cell transplantation (HCT) is a lifesaving treatment for people diagnosed with fatal blood cancers or other blood disorders. The procedure involves replacing the recipient’s blood ...

European Commission grants conditional marketing authorisation to Sanofi’s Rezurock to treat chronic graft-vs-host disease: Paris Wednesday, April 1, 2026, 11:00 Hrs [IST] The E ...

In addition to the EU, Rezurock is approved in 20 countries, including the US, UK, and Canada for the treatment of patients 12 years and older with chronic GVHD after failure of at least two prior ...